---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-044952"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2026-04-17T23:59:59+00:00"
generated_at: "2026-05-15T05:33:41.574554+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioXcel Therapeutics issues warrants to purchase 1.35M shares at $0.01 per share under credit amendment

## Summary
- On April 15, 2026, BioXcel Therapeutics granted lenders warrants to purchase up to 1,353,729 shares of common stock at an exercise price of $0.01 per share.
- The warrants were issued pursuant to the Ninth Amendment to the Credit Agreement and Guaranty, dated April 19, 2022.
- The Company also entered into a Fourth Amended and Restated Registration Rights Agreement with the lenders to register shares underlying the warrants.
- The lenders include entities such as Oaktree-TCDRS Strategic Credit, LLC, Oaktree Specialty Lending Corporation, and others.
- The warrants expire on the seventh anniversary of issuance and were issued in reliance on Section 4(a)(2) of the Securities Act.

## SEC filing metadata
- accession: 0001104659-26-044952
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2026-04-17T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465926044952/0001104659-26-044952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465926044952/tm2612008d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-044952
- JSON: https://secwatch.observer/filing/0001104659-26-044952.json
- Plain text: https://secwatch.observer/filing/0001104659-26-044952.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.